Anti-Human IL-23A (p19) (Risankizumab) - 50 mg

All|Recombinant Antibodies>Biosimilar Recombinant Antibodies|Primary Monoclonal Antibodies

2 - 8°C Wet Ice

IL-23 is a member of the IL-12 family of proinflammatory and immunoregulatory cytokines1and plays a key role in the differentiation and proliferation of type 17 helper T cells (Th17)2. IL-23 exists as a heterodimer composed of the IL-12p40 subunit and a novel p19 subunit that isshared with IL-393. IL-23 activities lead to the production of Th17-derived pro-inflammatorycytokines IL-17 and IL-221. Additionally, IL-23 possesses potent anti-tumor and anti-metastaticactivity in mouse models of cancer, suggesting a potential role for IL-23 in therapeutic treatmentof cancer4. IL-23 also contributes to chronic inflammation of immune-mediated diseasesincluding psoriasis and psoriatic arthritis2.Risankizumab is a humanized IgG monoclonal antibody that inhibits the proinflammatory effectsof IL-23 by binding to and neutralizing its p19 subunit5. Risankizumab was generated byimmunizing NMRI × C57/Bl6 mice with a hybrid mouse p40/human p19 recombinant cytokine6.The hybrid cytokine was produced in HEK293F mammalian cells as individual p40 and p19subunits with no linker, similar to native cytokines. Antibodies with high affinity binding torecombinant human IL-23 and the ability to inhibit human IL-23-induced IL-17 production inmouse splenocytes were selected. Epitope mapping identified residues 89-107 and 118-132 asthe IL-23 binding sites. Risankizumab binding prevents IL-23 receptor activation and disrupts the IL-23/Th17 axis5.Additionally, risankizumab inhibits IL-23 phosphorylation of STAT3 in human B-lymphoblastoid cell lines derived from human diffuse large cell lymphoma and inhibits inductionof IL-17 production from human IL-23 stimulation in mouse splenocytes. Risankizumab is also known as ABBV-066 and BI 655066. Risankizumab has been approved fortreatment of plaque psoriasis, psoriatic arthritis, Crohn’s Disease, and ulcerative colitis.

≥ 5.0 mg/ml

IL-23 is secreted by activated dendritic cells, macrophages, andmonocytes.